Insulin-like growth factor-I gene delivery to astrocytes reduces their inflammatory response to lipopolysaccharide
Open Access
- 3 March 2011
- journal article
- research article
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 8 (1) , 21
Abstract
Background: Insulin-like growth factor-I (IGF-I) exerts neuroprotective actions in the central nervous system that are mediated at least in part by control of activation of astrocytes. In this study we have assessed the efficacy of exogenous IGF-I and IGF-I gene therapy in reducing the inflammatory response of astrocytes from cerebral cortex.Methods: An adenoviral vector harboring the rat IGF-I gene and a control adenoviral vector harboring a hybrid gene encoding the herpes simplex virus type 1 thymidine kinase fused toAequorea victoriaenhanced green fluorescent protein were used in this study. Primary astrocytes from mice cerebral cortex were incubated for 24 h or 72 h with vehicle, IGF-I, the IGF-I adenoviral vector, or control vector; and exposed to bacterial lipopolysaccharide to induce an inflammatory response. IGF-I levels were measured by radioimmunoassay. Levels of interleukin 6, tumor necrosis factor-α, interleukin-1β and toll-like receptor 4 mRNA were assessed by quantitative real-time polymerase chain reaction. Levels of IGF-I receptor and IGF binding proteins 2 and 3 were assessed by western blotting. The subcellular distribution of nuclear factor κB (p65) was assessed by immunocytochemistry. Statistical significance was assessed by one way analysis of variance followed by the Bonferroni pot hoc test.Results: IGF-I gene therapy increased IGF-I levels without affecting IGF-I receptors or IGF binding proteins. Exogenous IGF-I, and IGF-I gene therapy, decreased expression of toll-like receptor 4 and counteracted the lipopolysaccharide-induced inflammatory response of astrocytes. In addition, IGF-I gene therapy decreased lipopolysaccharide-induced translocation of nuclear factor κB (p65) to the cell nucleus.Conclusion: These findings demonstrate efficacy of exogenous IGF-I and of IGF-I gene therapy in reducing the inflammatory response of astrocytes. IGF-I gene therapy may represent a new approach to reduce inflammatory reactions in glial cells.Keywords
This publication has 47 references indexed in Scilit:
- Central administration of insulin-like growth factor-I decreases depressive-like behavior and brain cytokine expression in miceJournal of Neuroinflammation, 2011
- Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunctionCellular Signalling, 2010
- Toll‐like receptor 4 in CNS pathologiesJournal of Neurochemistry, 2010
- Toll-like Receptor 4 Modulation as a Strategy to Treat SepsisMediators of Inflammation, 2010
- The ependymal route for insulin-like growth factor-1 gene therapy in the brainNeuroscience, 2009
- Modulation by insulin-like growth factor I of the phosphatase PTEN in astrocytesBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2008
- Statins enhance toll‐like receptor 4‐mediated cytokine gene expression in astrocytes: Implication of Rho proteins in negative feedback regulationJournal of Neuroscience Research, 2007
- TLR-4 and -6 agonists reverse apoptosis and promote maturation of simian virus 5-infected human dendritic cells through NFkB-dependent pathwaysVirology, 2007
- A new concept in neurodegeneration: TNFα is a silencer of survival signalsTrends in Neurosciences, 2000
- Bacterial Lipopolysaccharide Increases Prostaglandin Production by Rat Astrocytes via Inducible Cyclo-oxygenase: Evidence for the Involvement of Nuclear Factor κBBiochemical and Biophysical Research Communications, 1999